We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

136 hedge funds and large institutions have $556M invested in Vanda Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 53 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

15% more call options, than puts

Call options by funds: $721K | Put options by funds: $625K

11% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 19

2.13% less ownership

Funds ownership: 92.47% → 90.34% (-2.1%)

4% less funds holding

Funds holding: 141 → 136 (-5)

13% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 53

14% less capital invested

Capital invested by funds: $648M → $556M (-$92.5M)

Holders
136
Holders Change
-5
Holders Change %
-3.55%
% of All Funds
3.39%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
21
Increased
46
Reduced
53
Closed
19
Calls
$721K
Puts
$625K
Net Calls
+$96K
Net Calls Change
-$1.23M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$54.8M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$33.3M
3
AC
Armistice Capital
New York
+$14.7M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.62M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$7.43M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$16M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$11.7M
3
CM
Castleark Management
Illinois
-$9.31M
4
OAM
Oxford Asset Management
United Kingdom
-$7.95M
5
AL
AJO LP
Pennsylvania
-$7.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
PNC Financial Services Group
26
PNC Financial Services Group
Pennsylvania
$4.39M +$449K +31,510 +11%
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$4.31M -$364K -25,507 -8%
Deutsche Bank
28
Deutsche Bank
Germany
$4.23M +$551K +38,689 +15%
KCM
29
Kingdon Capital Management
New York
$4.04M -$1.86M -130,340 -31%
AL
30
AJO LP
Pennsylvania
$3.91M -$7.48M -525,112 -65%
CS
31
Candriam SCA
Luxembourg
$3.32M – – –
CS
32
Credit Suisse
Switzerland
$2.99M +$388K +27,252 +15%
Principal Financial Group
33
Principal Financial Group
Iowa
$2.97M -$42.8K -3,000 -1%
OAM
34
Oxford Asset Management
United Kingdom
$2.79M -$7.95M -557,905 -74%
SIM
35
Spark Investment Management
New York
$2.78M +$2.15M +150,800 +316%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$2.6M +$698 +49 +0%
UONDDL
37
University of Notre Dame du Lac
Indiana
$2.46M +$2.51M +176,056 New
GAM
38
Gotham Asset Management
New York
$2.35M +$1.54M +107,736 +179%
NI
39
Numeric Investors
Massachusetts
$2M -$5.04M -353,400 -71%
JP Morgan Chase
40
JP Morgan Chase
New York
$1.99M -$545K -38,261 -21%
IBT
41
International Biotechnology Trust
United Kingdom
$1.9M – – –
SCA
42
Secor Capital Advisors
New York
$1.88M +$253K +17,766 +15%
Allianz Asset Management
43
Allianz Asset Management
Germany
$1.81M -$151K -10,594 -8%
AI
44
Axiom Investors
Connecticut
$1.81M -$263K -18,420 -12%
Wells Fargo
45
Wells Fargo
California
$1.66M -$17.2K -1,207 -1%
Two Sigma Advisers
46
Two Sigma Advisers
New York
$1.6M -$663K -46,500 -29%
PP
47
PDT Partners
New York
$1.52M – – –
State Board of Administration of Florida Retirement System
48
State Board of Administration of Florida Retirement System
Florida
$1.51M – – –
Wellington Management Group
49
Wellington Management Group
Massachusetts
$1.5M -$836K -58,646 -35%
PAM
50
Panagora Asset Management
Massachusetts
$1.5M +$526K +36,894 +53%
1
2
3 4 5

VNDA Hedge Fund Activity: Q1 2017 in Review

136 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2017, worth a combined $556M — down 14% from $648M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new VNDA positions and 19 closed out — a net gain of 2 holders — while 46 added to existing stakes and 53 trimmed.

The largest buyer was BlackRock, adding an estimated $54.8M. The largest seller was Deerfield Management, cutting an estimated $16M.

  • 136 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2017, down from 141 in Q4 2016.
  • Funds reported $556M of Vanda Pharmaceuticals stock for Q1 2017, down 14% quarter-over-quarter.
  • 21 funds opened new Vanda Pharmaceuticals positions in Q1 2017 and 19 closed out, a net change of +2 holders.
  • The largest Vanda Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $54.8M added.
  • The largest Vanda Pharmaceuticals seller in Q1 2017 was Deerfield Management, an estimated $16M sold.

Based on aggregated 13F filings for Q1 2017.